High-Throughput Transcriptomic and RNAi Analysis Identifies AIM1, ERGIC1, TMED3 and TPX2 as Potential Drug Targets in Prostate Cancer

• Paula Vainio,

  Affiliation VTT Technical Research Centre of Finland, and Turku Centre for Biotechnology, University of Turku, Turku, Finland

  ⨯
• John-Patrick Mpindi,

  Affiliation Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland

  ⨯
• Pekka Kohonen,

  Affiliation VTT Technical Research Centre of Finland, and Turku Centre for Biotechnology, University of Turku, Turku, Finland

  ⨯
• Vidal Fey,

  Affiliation VTT Technical Research Centre of Finland, and Turku Centre for Biotechnology, University of Turku, Turku, Finland

  ⨯
• Tuomas Mirtti,

  Affiliations Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland, Haartman Institute, Department of Pathology, University of Helsinki, Helsinki, Finland, HUSLAB, Department of Pathology, Helsinki University Central Hospital, Helsinki, Finland

  ⨯
• Kalle A. Alanen,

  Affiliation Department of Pathology, Turku University Hospital and University of Turku, Turku, Finland

  ⨯
• Merja Perälä,

  Affiliation VTT Technical Research Centre of Finland, and Turku Centre for Biotechnology, University of Turku, Turku, Finland

  ⨯
• Olli Kallioniemi,

  Affiliations VTT Technical Research Centre of Finland, and Turku Centre for Biotechnology, University of Turku, Turku, Finland, Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland

  ⨯
• Kristiina Iljin

  * E-mail: kristiina.iljin@gmail.com

  Affiliation VTT Technical Research Centre of Finland, and Turku Centre for Biotechnology, University of Turku, Turku, Finland

  ⨯